Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering into a global licensing agreement to develop and commercialize up to five biosimilar candidates including SB36, a biosimilar referencing Takeda Pharmaceutical’s Entyvio (vedolizumab) – deepening the collaboration between the South Korean biologics manufacturer and the Swiss generic drug giant.
Strategic Pattern: Sandoz leverages Samsung Bio’s manufacturing scale and biosimilar development expertise; Samsung Bio gains global commercialization infrastructure and regulatory access in key markets
Market Impact & Outlook
Biosimilar Market Dynamics: Global biosimilar market projected to exceed US$60 billion by 2030; inflammatory bowel disease (IBD) biologics (anti‑TNF, anti‑integrin) represent high‑value targets with significant originator revenue at risk from patent expirations (Entyvio EU patent expiry ~2028, US ~2030).
SB36 Competitive Positioning: Vedolizumab biosimilar pipeline crowded (Celltrion, Biocon, others in development); Samsung Bio + Sandoz partnership combines manufacturing excellence with established GI/Gastroenterology commercial footprint – critical for formulary access against reference Entyvio and other biosimilar entrants.
Sandoz Biosimilar Strategy: Expanded Samsung Bio partnership reinforces Sandoz’s position as global biosimilar leader (post‑Novartis spin‑off); five‑candidate deal provides pipeline depth beyond current marketed portfolio (Zessly, Hyrimoz, Erelzi).
Samsung Bioepis Portfolio Diversification: Expanded Sandoz collaboration reduces dependency on single‑partner concentration; SB36 adds GI therapeutic area to existing immunology (Pyzchiva) and rare disease (Epysqli) presence; estimated US$200‑300 million peak annual revenue potential for SB36 assuming 20‑25% global biosimilar market share.
Regulatory & Launch Timeline: SB36 pre‑clinical status suggests Phase I initiation 2026‑2027, potential approval 2030‑2031 (US/EU) contingent on reference product patent litigation outcomes; Sandoz legal expertise and settlement track record (Stelara, Humira) de‑risks launch timing uncertainty.
Forward‑Looking Statements This brief contains forward‑looking statements regarding partnership scope, development timelines, and commercial expectations for SB36 and additional biosimilar candidates. Actual results may differ due to risks including patent litigation, regulatory approval delays, competitive biosimilar entrants, and manufacturing scale‑up challenges.-Fineline Info & Tech
By Fineline Cube